NCT01101581 - Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | Biotech Hunter

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2016

Study Completion Date

March 31, 2017

Conditions

Non Hodgkin's LymphomaNHLAggressive NHLDiffuse Large B-cell Lymphoma

Interventions

DRUG

Veltuzumab and 90Y-Epratuzumab Tetraxetan

Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 \& 3 (days 8 \& 15).

DRUG

90Y-epratuzumab tetraxetan

DRUG

veltuzumab

Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23

Trial Locations (7)

10021

Weill Med College of Cornell Univ/NYH, New York

19104

University of Pennsylvania Cancer Center, Philadelphia

19713

Helen F. Graham Cancer Center, Newark

32806

MDACC Orlando, Orlando

33612

Moffitt Cancer Center, Tampa

46526

Goshen Center for Cancer Care, Goshen

55905

Mayo Clinic, Rochester